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Abstract
When loss of heterozygosity (LOH) is correlated with loss or gain of a disease phenotype, it
is often necessary to identify which gene or genes are involved. Here, we developed a
region-specific LOH-inducing system based on mitotic crossover in human induced pluripo-
tent stem cells (hiPSCs). We first tested our system on chromosome 19. To detect homozy-
gous clones generated by LOH, a positive selection cassette was inserted at the AASV1
locus of chromosome 19. LOHs were generated by the combination of allele-specific dou-
ble-stranded DNA breaks introduced by CRISPR/Cas9 and suppression of Bloom syn-
drome (BLM) gene expression by the Tet-Off system. The BLM protein inhibitor ML216
exhibited a similar crossover efficiency and distribution of crossover sites. We next applied
this system to the short arm of chromosome 6, where human leukocyte antigen (HLA) loci
are located. Genotyping and flow cytometric analysis demonstrated that LOHs associated
with chromosomal crossover occurred at the expected positions. Although careful examina-
tion of HLA-homozygous hiPSCs generated from parental cells is needed for cancer predis-
position and effectiveness of differentiation, they may help to mitigate the current
shortcoming of hiPSC-based transplantation related to the immunological differences
between the donor and host.
Introduction
We and others have previously reported a method to induce loss of heterozygosity (LOH) in
mouse embryonic stem cells (ESCs) under suppression of the Bloom syndrome (Blm) gene [1]
[2] [3]. Suppression of Blm enhanced the rate of mitotic recombination, and crossovers
occurred randomly across the observed chromosome [4]. When DNA double-stranded breaks
(DSBs) were introduced by meganuclease I-SceI under Blm suppression, the rate of LOH was
further enhanced by crossovers at sites close to the allele-specific I-SceI-cutting site [4]. We
analyzed mouse ESC clones after generating the crossovers and found that LOH occurred
across entire genomic regions from crossover points to telomeres.
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To date, a system that induces LOH in a targeted region on a specific chromosome in cells,
such as human induced pluripotent stem cells (hiPSCs), has not been established yet. We
hypothesized that a feasible method to generate region-specific LOH in hiPSC lines would be
as follows. Assuming that parental hiPSCs bear a heterozygous mutation on the target chromo-
some and an allele-specific DSB is introduced on that chromosome during the 4N stage of the
cell cycle, the genomic region from the site of the DSB to the telomere would contain either a
homozygous mutation or no mutation after crossover and chromosome segregation (Fig 1A).
This phenomenon can then be used to identify genes responsible for certain diseases. When
the mutation “X” is a dominant mutation (parental hiPSCs have the disease phenotype), some
of the clones do not have the disease phenotype after crossover (case #b in Fig 1A). However,
when X is a recessive mutation (parental hiPSCs do not have the disease phenotype), some of
the clones have the disease phenotype after crossover (case #a in Fig 1A).
This study revealed that both allele-specific DSBs mediated by CRISPR/Cas9 and BLM sup-
pression allow targeted homozygosity in hiPSCs. Therefore, this system is applicable to in vitro
genetic analysis of hiPSCs, when crossbreeding experiments are not possible.
Methods
Vector construction
BLM-targeting vector: To prepare the human BLM-targeting vector, we changed the tk pro-
moter to the hPGK promoter and modified the Kozak sequence for tTA translation from
AGGATT to GCCACC in the mouse Blm-targeting vector [1]. We also removed the artificial
intron sequence from the mouse Blm-targeting vector [1]. The left and right arms of the target-
ing vector were prepared by PCR using primers hBLMLarmF1 and hBLMLarmR1, and
hBLMRarmF1 and hBLMRarmR3, respectively (S1 Table). Chromosome 19 AAVS1-vector
construction with the cNP cassette: The cNP cassette used in this study was derived from the
cNP cassette used in mouse ESCs [2] with the following three modifications. The Pgk promoter
was changed to the hEF1α promoter, the Δtk gene was removed, and Lox2272s were replaced
by loxPs. The left and right arms of the targeting vector were prepared by PCR using primers
AAVS1-LF1 and AAVS1-LR1, and AAVS1-RF1 and AAVS1-RR1, respectively (S1 Table).





mosome 7, bp 39519983–39520225: GRCh38) [5] was flanked by the cNP cassette. The insula-
tor and cNP cassette were inserted into the piggyBac transposon vector [6], resulting in the
cNP in PB. The left and right arms of the targeting vector were prepared by PCR using primers
chr6-Asc1-up and chr6-Asc1-low, and chr6-Pac1-up and chr6-Pac1-low, respectively (S1
Table). The iCre gene was expressed under the control of the EF1α promoter.
Cell culture
hiPSC lines [7] were grown in hESC serum-free human ESC (hESC) medium consisting of
DMEM/F-12 (Life Technologies) supplemented with 20% knockout serum replacement (Life
Technologies), 2 mM L-glutamine, 1× nonessential amino acids (Life Technologies), 0.1 mM
2-mercaptoethanol, and 5 ng/mL basic fibroblast growth factor (Katayama Chemical Indus-
tries) on Synthemax II-SC-coated tissue culture dishes (Corning). The cells were passaged
using Accutase (Sigma) and seeded with the Rho kinase inhibitor Y-27632 (10 μM; LC
Laboratories).
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Targeting
To target the BLM locus, hiPSCs were transfected as a single cell suspension by electroporation
(Neon Transfection System; Invitrogen) using 1 × 106 cells in a 100 μL tip with 8 μg total DNA
(TALEN left, 2 μg; TALEN right, 2 μg; BLM-targeting vector, 4 μg). TALEN sequences are
shown in S2 Table. After one pulse of electroporation at 1,100 V with a 30 ms pulse width, the
cells were plated on Synthemax II-SC-coated tissue culture dishes in hESC medium containing
10 μM Y-27632 without puromycin. Selection was initiated with 0.5 μg/mL puromycin at 2
days after transfection. The targeted clones were first selected by PCR with primers hBLM-3
and tTA2, and then the targeted biallelic clones (BLMtet/tet hiPSCs) were chosen by PCR with
primers hBLM-1, hBLM-2, and tTA-1. Then, the selection cassettes were removed by Flippase
Fig 1. Establishment of a BLM transcript regulation system and detection of crossovers by a reporter cassette in hiPSCs. (A) Schematic representation of a
crossover induced by a double-stranded DNA break during the 4N stage of the cell cycle in hiPSCs. X is a dominant mutation. After segregation, case #a cells have
the disease phenotype, while case #b cells are normal. (B) Targeting of the Tet-Off cassette to both alleles of the BLM locus with the assistance of TALEN (BLMtet-
puro/tet-puro). The selection cassettes were removed by Flippase (Flpo), the hiPSC-BLMtet/tet cells were established. (C) Electrophoresis of qRT-PCR products. Total
RNA from 2 × 105 hiPSC-BLMtet/tet cells was collected at days 0, 5, and 7 after dox treatment, and qRT-PCR was performed. (D) Histogram data represent the
mean ± SEM of three independent experiments. Comparison of two groups with normally distributed variables was performed using the Student’s t-test by Kaleida
Graph software. (E) Targeting of the double selection cassette (cNP) to the AAVS1 locus (hiPSC-BLMtet/tetAAVScNP/+). (F) Schematic representation of mitotic
crossover during the 4N stage. DSBs were introduced by CRISPR/Cas9.
https://doi.org/10.1371/journal.pone.0225740.g001
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(Flpo), and the hiPSC-BLMtet/tet cells were thereby established (S1 Table). To target the AAVS1
locus, BLMtet/tet hiPSCs were transfected as a single cell suspension by electroporation using
1 × 106 cells in a 100 μL tip with 8 μg total DNA (AAVS1-ZFN left, 2 μg; AAVS1-ZFN right,
2 μg; AAVS1-targeting vector, 4 μg). The AAVS1-ZFN sequences have been described previ-
ously [8]. After one pulse of electroporation at 1,200 V with a 30 ms pulse width, the cells were
plated on Synthemax II-SC-coated tissue culture dishes in hESC medium containing 10 μM Y-
27632 without G418. Selection was initiated with 100 μg/mL G418 at 2 days after transfection.
The targeted clones were first selected by PCR with primers AAVS1-LF2 and Puro-L2, and
then the targeted monoallelic clones (BLMtet/tet AAVS1cNP/+hiPSCs) were chosen by PCR with
primers AAVS1-C-F, AAVS1-C-R, and Puro-L2 (S1 Table). To target the telomeric region of
the short arm of chromosome 6, hiPSCs were transfected as a single cell suspension by electro-
poration using 1 × 106 cells in a 100 μL tip with 8 μg pX330 (AGAAAATAGCCGCCACTTAA
as the gRNA) and 3.5 μg HLA-targeting vector with cNP in PB. After one pulse of electropora-
tion at 1,200 V with a 30 ms pulse width, the cells were plated on Synthemax II-SC-coated tis-
sue culture dishes in hESC medium containing 10 μM Y-27632. Selection was initiated with
100 μg/mL G418 at 2 days after transfection. The concentration of G418 was increased to
150 μg/mL at 4 days post-transfection. The targeted clones were first selected by PCR with
primers chr6-TG-up and hEF1a-TG, and then the targeted monoallelic clones (telHLAcNP/
+hiPSCs) were chosen by PCR with the primers chr6-TG-up, chr6-TG-low, and hEF1a-TG (S1
Table).
Introduction of allele-specific DSBs in chromosome 19
BLMtet/tetAAVS1cNP/+ hiPSCs were transfected as a single cell suspension by electroporation
using 1 × 106 cells in a 100 μL tip with 9.5–11 μg total DNA (6.5–8.0 μg pX330 containing vari-
ous gRNA sequences and 3 μg iCre recombinase plasmid). BLMtet/tetAAVS1cNP/+ hiPSCs were
pretreated with dox (1 μg/mL) from 7 days before transfection. The gRNA sequences are listed
in S3 Table. After one pulse of electroporation at 1,300 V with a 20 ms pulse width, the cells
were plated on Synthemax II-SC-coated tissue culture dishes in hESC medium containing
10 μM Y-27632 without puromycin or G418. At 2 days after transfection, selection was initi-
ated with 0.5 μg/mL puromycin. At 4 days after transfection, the selection condition was
changed to 1 μg/mL puromycin and 100 μg/mL G418. At 6 days after selection, the G418 con-
centration was increased to 200 μg/mL G418.
Introduction of allele-specific DSBs in chromosome 6
telHLAcNP/+ hiPSCs were transfected using the same protocol for chromosome 19. The gRNA
sequences are listed in S3 Table. ML216 (12.5 μM) was applied from 12 h before transfection
until 2 days after transfection. At 2 days post-transfection, selection was initiated with 0.2 μg/
mL puromycin. At 4 days post-transfection, the selection condition was changed to 0.25 μg/
mL puromycin and 25 μg/mL G418. At 6 days after selection, the selection condition was
changed again to 0.33 μg/mL puromycin and 50 μg/mL G418.
RNA extraction and quantitative real-time polymerase chain reaction
(qRT-PCR)
Total RNA was extracted from cells with an RNeasy Plus Micro Kit (Qiagen). First-strand
cDNA was synthesized from 800 ng total RNA with random hexamer primers using Super-
Script III (Invitrogen) at 50˚C for 60 min. qRT-PCR was performed to measure BLM gene
expression. Total RNA was reverse transcribed to cDNA using the SuperScript III First-Strand
Synthesis System for qRT-PCR (Invitrogen). qRT-PCR was performed with the Applied
Generation of targeted homozygosity in hiPSCs
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Biosystems 7900HT Fast Real-Time PCR System using the following PCR primer sets:
RTPCR-leader-F and RTPCR-exon3-R, hActb-RTPCR-F, and hActb-RTPCR-R (S1 Table).
Quantification of pluripotency marker gene expression
Total RNA was isolated from parental fibroblasts, hiPSC-telHLAcNP/+, and hiPSC-telHLAcNP/
+ML216(+)HLA I-III-CRISPR(+). Library preparation was performed using a TruSeq
stranded mRNA sample prep kit (Illumina, San Diego, CA), according to the manufacturer’s
instructions. Whole transcriptome sequencing was applied to the RNA samples through Illu-
mina HiSeq 2500 and 3000 platforms in the 75-base single-end mode. Illumina Casava
ver.1.8.2 software was used for base calling. The sequenced reads were mapped to human ref-
erence genome sequences (hg19) using TopHat ver. 2.0.13 in combination with Bowtie2 ver.
2.2.3 and SAMtools ver. 0.1.19. The number of fragments per kilobase of exon per million
mapped fragments (FPKM) was calculated using Cufflinks ver. 2.2.1. The FPKM values were
calculated from the respective sequence data, and the analyses were performed using iDEP85
(http://bioinformatics.sdstate.edu/idep/). The SNP-array data have been deposited in the
Genomic Expression Omnibus under accession number (GSE134441,GSE137657,
GSE138093).
Screening for positive clones with crossover occurring in chromosomes 19
and 6
DNA was extracted from hiPSCs with a DNeasy Blood & Tissue Kit (Qiagen). Competitive
PCR was performed to detect positive clones of chromosome 19 using primers AAVS1-C-F,
AAVS1-C-R, and Puro-L2 (S1 Table). Cycling conditions were initial denaturation at 94˚C for
2 min, followed by 35 cycles of 98˚C for 10 s, 68˚C for 90 s, and 72˚C for 7 min. The wildtype
allele was detected at 275 bp, the neomycin-selective allele was detected at 407 bp, and the
puromycin-selective allele was detected at 1,435 bp (S1 Fig). We performed the same screening
for positive clones of chromosome 6 using primers chr6-TG-up, chr6-C-low, and Puro-L2 (S1
Table). The wildtype allele was detected at 924 bp, the neomycin-selective allele was detected at
1,355 bp, and the puromycin-selective allele was detected at 2,264 bp (data not shown).
Determination of crossover points in chromosomes 19 and 6
First, we identified heterozygous SNPs by referring to the SNP database dbSNP https://www.
ncbi.nlm.nih.gov/snp (S4 Table). After identifying positive clones by competitive PCR, we
extracted the genomic DNA and analyzed the crossover points (S4 Table). We defined the
crossover points as the positions equidistant from the heterozygous and homozygous SNPs.
HLA genotyping
First, target DNA was amplified by PCR using group-specific primers LABType SSO HLA A
Locus, LABType SSO HLA B Locus, LABType SSO HLA C Locus, and LABType SSO HLA
DRB1. The PCR products were biotinylated, allowing detection with R-phycoerythrin-conju-
gated streptavidin. The PCR products were denatured and allowed to rehybridize to cDNA
probes conjugated with fluorescently coded microspheres (One Lambda). A LABScan 100
flow analyzer (One Lambda) identified the fluorescence intensity of phycoerythrin on each
microsphere. HLA alleles or allele groups were determined in the sample by matching the pat-
tern of positive and negative bead IDs with the information in the LABType SSO worksheet or
using HLA Fusion 4.1 HotFix 2 (both from One Lambda).
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Flow cytometry
hiPSC suspensions were washed with phosphate-buffered saline containing 1% (w/v) bovine
serum albumin and 0.05% (v/v) sodium azide and then incubated with the appropriate anti-
bodies for 30 min in the dark on ice. Samples were analyzed on a BD FACSCanto II (BD Bio-
sciences). Data were analyzed with FlowJo software (Tomy Digital Biology). The antibodies
used for flow cytometry were a FITC-conjugated anti-HLA-A2 antibody (343303; BioLegend),
anti-HLA-A32/25 monoclonal IgM antibody (0136HA; One Lambda), and Alexa Fluor
647-conjugated goat anti-mouse IgM (ab150123; Abcam).
SNP array analysis
To analyze the SNP copy number, genomic DNA was isolated from parental fibroblast,
hiPSCs, hiPSC-BLMtet/tetAAVS1cNP/+, hiPSC-BLMtet/tetAAVS1cNP/+–Dox(+)9M-CRISPR(+),–
Dox(+)14M-CRISPR(+),–Dox(+)19M-I-CRISPR(+),–ML216(+)9M-CRISPR(+),–ML216(+)
14M-CRISPR(+),–ML216(+)19M-I-CRISPR(+), and hiPSC-telHLAcNP/+ML216(+)HLA I-III--
CRISPR(+) and hybridized to an Infinium Omni5-4 v1.2 BeadChip (Illumina). Data were ana-
lyzed using GenomeStudio (Illumina). The SNP array data have been deposited in the
Genomic Expression Archive under accession number E-GEAD-283.
Results
Establishment of a BLM transcript regulation system and detection of
crossovers by a reporter cassette in hiPSCs
A Tet-Off cassette was used for transient suppression of BLM expression. The Tet-Off cassette
used for mouse ESCs [1] was modified and inserted into both alleles of the BLM locus with the
assistance of transcription activator-like effector nucleases (TALENs) followed by removal of
the selection cassette (S1 Fig), resulting in the BLMtet/tet allele (Fig 1B). The level of BLM tran-
scripts in BLMtet/tet hiPSCs without the addition of doxycycline (dox) was equivalent to that
observed in parental hiPSCs (S2 Fig) The BLM expression level was then checked at 7 days
after the addition of 1 μg/mL dox, and BLM transcripts were measured by quantitative PCR
(qPCR). The transcripts in BLMtet/tet hiPSCs were downregulated to 20% of that in the control
(Fig 1C and 1D). We also performed 8 days of treatment with 1 μg/mL dox and found that the
level of BLM transcripts was approximately 15% of that in the control (S3 Fig), and BLMtet/tet
hiPSCs appeared to be unhealthy with longer exposure to dox. Thus, we chose 7 days of treat-
ment with dox.
To detect crossover events in the hiPSCs, a conditionally convertible selection cassette
(cNP) was first inserted at the safe-harbor AAVS1 locus of chromosome 19, resulting in the
BLMtet/tet AAVS1cNP/+ allele (Fig 1E) [2]. The cNP cassette included neomycin (N) and puro-
mycin (P) resistance genes. The N and P genes were arranged in a tail-to-tail configuration
and flanked by inversely oriented loxP sequences. Under the default condition, the promoter
in front of N drove expression of N but not P, resulting in G418-resistant and puromycin-sen-
sitive hiPSCs (NRPS). Upon codon-improved Cre recombinase (iCre) expression, inversion of
the cNP cassette occurred, resulting in loss of G418 resistance and gain of puromycin resis-
tance. We used iCre to enhance Cre-mediated cassette inversion [9]. The iCre-mediated cas-
sette inversion was estimated by surviving colonies after the drug selections (S4 Fig). Since the
surviving colonies with puromycin were approximately 20%-30% of those with G418, the effi-
ciency of the inversion was 20%-30%. Next, allele-specific DSBs mediated by the CRISPR/Cas9
system were introduced centromeric to the cNP cassette. If crossover occurred in the chromo-
some bearing the cNP cassette during the 4N stage of the cell cycle, the cNP cassette would be
Generation of targeted homozygosity in hiPSCs
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duplicated after segregation (Fig 1F). These cassette-duplicated cells were selected by both
G418 and puromycin after Cre-mediated recombination (NRPR).
This positive selection approach differs from the negative selection used previously, based
on loss of genes encoding herpes simplex virus thymidine kinase (TK) or green fluorescent
protein (GFP). Recently, Sadhu et al. reported that negative selection based on loss of the gfp
gene successfully identified yeast clones bearing LOH following the introduction of allele-spe-
cific DSBs with the CRISPR/Cas9 system [10]. LOH is often associated with genomic deletion
in mammalian cells, and negative selection cannot exclude clones bearing these deletion events
[4]. In fact, Riolobos et al. reported that an HLA-homozygous cell line was derived from an
HLA-heterozygous human ESC line by negative selection with TK, but the efficiency of cross-
over events was unexpectedly low [11]. Although they eventually determined the crossover
point, it could not be predicted by their system. In contrast, positive selection is able to exclude
deletion events. However, it cannot exclude aberrant cassette duplication due to chromosomal
or locus amplifications without crossover [2]. However, such aberrant events can be evaluated
by competitive PCR to detect whether the wildtype allele is present (S5 Fig).
Generation of clones with crossovers in chromosome 19
Preliminary experiments were performed on chromosome 19 where the cNP cassette was
inserted at the AAVS1 locus. To introduce allele-specific DSBs, we first searched for SNPs in
sequences corresponding to that of the protospacer adjacent motif (PAM) and then designed a
single guide RNA (sgRNA) for CRISPR/Cas9. The locations of the allele-specific DSBs were 9,
14, and 19 Mb from the centromere of chromosome 19. The overall procedure used to isolate
the positive clones is shown in Fig 2A.
Suppression of BLM transcripts by dox started at 7 days before transfection, and selection
was performed by gradually increasing the G418 and puromycin concentrations (Fig 2A).
Because we wanted to eliminate hiPSCs that did not undergo iCre-mediated inversion, we
started puromycin selection before the double selection. First, we compared various condi-
tions, BLM suppression only, DSBs at 9 Mb only, and the combination of BLM suppression
and DSBs at 9 Mb, to acquire positive clones with possible crossover. As shown in Fig 2B, we
obtained positive clones only when combining BLM suppression and DSBs. These results were
strikingly different from the previously reported data. In yeast, positive clones with crossovers
were obtained by CRISPR-mediated DSBs without suppression of the BLM homolog Sgs1 [10].
Moreover, whereas we could not obtain positive clones by BLM suppression only, Yamanishi
et al. reported that Blm suppression alone was sufficient to induce crossover in mouse ESCs.
These contrasting results between hiPSCs and mouse ESCs may be due to either the differing
efficiency of BLM/Blm suppression, the differing characteristics of the used cell lines (hiPSCs
vs. mouse ESCs), or both. Incomplete suppression of BLMmay also be a reason for the low
number of colonies.
We next analyzed crossover points after the introduction of DSBs and BLM suppression.
The parental hiPSC line had many heterozygous SNPs along each chromosome, and crossover
points should have occurred between SNP-heterozygous and -homozygous (LOH) sites. We
tentatively defined crossover points equidistant to the SNP-heterozygous and -homozygous
(LOH) sites. We detected crossover points close to the DSB sites at the chromosomal level
(S6A Fig). As shown by the LOH panel in Fig 2C, more detailed analyses at the 9 Mb position
revealed that, when crossover occurred centromeric to the DSBs, the distance between the
crossovers and DSBs was relatively small (~20 kb). Note that, because all clones were derived
from different dishes of cells, clones #1–#8 were an independent clone. In contrast, when
crossover occurred telomeric to the DSBs, this distance was relatively large (~300 kb). Clone
Generation of targeted homozygosity in hiPSCs
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#25 was exceptional and probably derived from uniparental disomy or a spontaneous DSB
close to the centromere, which was independent of the DSB induced by CRISPR/Cas9. Similar
distribution patterns were observed at 14 Mb (S6B Fig). To further evaluate this biased distri-
bution pattern, we established two more DSBs (19 Mb-I and 19 Mb-II) close to each other, and
the location of 19 Mb-I was centromeric to 19 Mb-II (S6C Fig). Again, both DSBs induced
crossovers centromeric to the DSBs. The crossover points induced by 19 Mb-II was not
observed for 19 Mb-I. These data implied that the biased distribution pattern was inherent and
not influenced by the genome sequence or structure.
SNP array analysis reveals introduction of homozygosity telomeric to the
DSB
The predicted outcome post-crossover in this study would be the same copy numbers (two
copies) of the genome and homozygous SNPs telomeric to the DSB. This prediction was
Fig 2. Generation and analyses of clones with crossovers in chromosome 19. Procedure for the isolation of NRPR clones under the condition of BLM transcript
suppression. hiPSC-BLMtet/tetAAVS1cNP/+ cells were treated with or without dox from 7 days before transfection to the day of transfection. Selection started 2 days
after transfection, either with or without the introduction of an allele-specific DSB. (B) Efficiency of crossover under the various conditions at the 9 Mb region of
chromosome 19. We picked 439 colonies (eight trials) and performed genotyping (S5 Fig). Bar indicates SEM. (C) Distribution of crossover points at 9 Mb from
the centromere of chromosome 19. Twenty-fiveNRPR-positive clones were isolated and analyzed using LOH panels and SNP arrays. Open squares indicate the
heterozygous genotype. Closed black squares indicate the loss of heterozygosity (LOH) genotype. The DSBs introduced by the CRISPR/Cas9 system are indicated
by scissors. (D) A schematic representation of chromosome 19 is shown at the top of the figure. After crossover, SNP array analysis indicated that the genome
derived from hiPSC-BLMtet/tetAAVS1cNP/+ Dox(+)9M-CRISPR(+) cells showed homozygosity telomeric to DSB and that the cells maintained two copies of the
genome.
https://doi.org/10.1371/journal.pone.0225740.g002
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assessed by an SNP array. When the DSB was introduced at the 9 Mb position of chromosome
19, a homozygous SNP pattern was observed telomeric to the DSB on chromosome 19 (9 Mb)
(Fig 2D).
BLM protein inhibitor ML216 has a similar effect on crossovers in
chromosome 19
For hiPSC-mediated therapeutics, exogenous genetic materials are undesirable, such as the
Tet-Off cassette in the BLM gene. We therefore also examined inhibitors of the BLM protein.
Nguyen et al. reported that a small molecule inhibitor, ML216, shows strong selectivity for
BLM in cultured cells [12]. More recently, Lazzarano et al. showed that ML216 induces mitotic
crossover in mouse ESCs. They also reported that transient suppression of the BLM protein
did not increase aneuploidy [13]. The procedure used to isolate positive clones generated with
the BLM inhibitor ML216 is shown in Fig 3A.
The efficiency of crossover with ML216 was similar to that with BLM transcript suppression
and dox treatment (Fig 3B). The LOH panel and SNP array analyses showed in a similar pat-
tern of suppression to that induced by the Tet-Off system (Fig 3C and 3D). The effect of
ML216 was further evaluated by SNP array analyses at 14 Mb and 19 Mb-I, and a similar cross-
over pattern was observed (Fig 3E). We performed further SNP analyses with whole chromo-
somes and we found that the crossover only occurred at the predicted sites (S7 Fig).
Combination of BLM inhibitor ML216 and DSBs results in homozygosity
of HLA class I genes in the short arm of chromosome 6
Because HLA genes are highly polymorphic, most individuals have two HLA haplotypes,
namely the HLA-heterozygous state. When established hiPSCs or their differentiated cells,
which are most likely HLA-heterozygous, are used for therapeutics as donor cells, the recipient
must have the same combination of HLA haplotypes. Our strategy is able to induce HLA
homozygosity in the entire region of the HLA locus. Therefore, we can easily choose a much
less incompatible combination between the donor of HLA-homozygous hiPSC-derived differ-
entiated cells and recipient.
To generate HLA-homozygous hiPSCs, we inserted the cNP cassette into a piggyBac trans-
poson vector within the telomeric region of the short arm of chromosome 6, where HLA genes
are located (hiPSC-telHLAcNP/+). Then, we introduced an allele-specific DSB between HLA
class I and III genes under inhibition of the BLM protein by ML216. The procedure used to
isolate the HLA-homozygous clones is shown in Fig 4A, and the location of DSBs introduced
by CRISPR/Cas9 and the HLA genotype in parental hiPSCs are schematically presented in Fig
4B.
We obtained two independent positive clones and analyzed the crossover points. Both
crossover points were nearby and centromeric to the DSB (Fig 4C, left). The HLA genotypes
were consistent with the crossover points (Fig 4C, right). SNP array analysis revealed a homo-
zygous SNP pattern in the short arm of chromosome 6 telomeric to the DSB (Fig 4D), which
was consistent with the pattern predicted post-crossover. We analyzed expression of marker
genes for pluripotency and found that their expression in hiPS-telHLA cNP/+ ML216(+) HLA
I-III-CRISPR (+) was similar to that in hiPS-telHLA cNP/+. These data suggested that the clones
maintained pluripotency after crossovers (S8 Fig). To confirm the crossovers, we analyzed the
surface expression of HLA class I molecules with a haplotype-specific monoclonal antibody
against HLA-A (Fig 4E). hiPSC-telHLAcNP/+ expressed both A32 and A2 haplotypes (S9 Fig).
In contrast, hiPSCs after crossover expressed only the A2 haplotype. We therefore successfully
Generation of targeted homozygosity in hiPSCs
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generated HLA-homozygous hiPSCs, and this strategy can be used for any human genomic
region to induce homozygosity followed by functional genomics.
Discussion
To establish HLA-homozygous hiPSCs, we used two genetic elements: the Tet-Off cassette to
suppress BLM expression and the cNP cassette for positive selection. However, for hiPSC-
mediated therapeutics, it is preferable to avoid the use of exogenous genetic elements. We
therefore also demonstrated successful substitution of the Tet-Off cassette with a small mole-
cule BLM inhibitor, ML216. In the future, we hope to evaluate the effects of ML216 on the
human genome by next generation sequencing, because BLM suppression results in genome
instability.
Fig 3. BLM protein inhibitor ML216 has a similar effect on crossovers in chromosome 19. Procedure for the isolation of NRPR clones under the
condition of BLM protein inhibition. hiPSC-BLMtet/tetAAVS1cNP/+ cells were treated with ML216 from 12 h before transfection to 1 day after transfection.
(B) Efficiency of crossover with ML216 treatment at the 9 Mb region of chromosome 19. Bar indicates SEM. (C) Distribution of the crossover points at 9
Mb under inhibition of the BLM protein by ML216. We picked 126 colonies (three trials) and performed genotyping (S5 Fig). TenNRPR-positive clones
were isolated and analyzed using LOH panels and SNP arrays. Open squares indicate the heterozygous genotype. Closed black squares indicate the loss of
heterozygosity (LOH) genotype. DSBs introduced by the CRISPR/Cas9 system are shown by scissors. (D) SNP array analysis of hiPSC-BLMtet/
tetAAVS1cNP/+ ML216(+)9M-CRISPR (+) cells. (E) Comparison of crossover points introduced by suppression of BLM transcripts (lanes 1 and 3) or
inhibition of the BLM protein by ML216 (lane 2 and 4). DSBs were introduced at 14 Mb (lanes 1 and 2) or 19 Mb-I (lanes 3 and 4).ML216 was added at
0.5 day before transfection.
https://doi.org/10.1371/journal.pone.0225740.g003
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We cloned the cNP cassette into the piggyBac transposon vector that is removable by piggy-
Bac transposase without any footprint after positive selection [14]. In addition, the cNP cas-
sette was flanked by insulator sequences for its stable expression. By using the combination of
the small molecule BLM inhibitor and piggyBac transposon vector, it may be possible to estab-
lish HLA-homozygous hiPSCs without any exogenous genetic elements.
Recently, Wang et al. reported Cas9-mediated chromosomal allelic exchange in mouse
somatic tissue [15]. This novel technology resulted in the repair of compound heterozygous
recessive mutations. However, unlike in our study, allelic exchange was expected to occur dur-
ing the 2N phase, but not the 4N phase, so that any genomic region would not be
homozygous.
HLA complex genes are located within the 6p21.3 region of the short arm of chromosome 6
and comprise more than 220 genes. Most of these genes are involved in immune functions.
Because HLA genes are highly polymorphic, most individuals have two HLA haplotypes, i.e.,
the HLA-heterozygous state. When established hiPSCs or their differentiated cells, which are
Fig 4. Combination of BLM inhibitor ML216 and DSBs equidistant to the HLA class III and I genes in the short arm of chromosome 6 results in
homozygosity of HLA class I. (A) Procedure for the isolation of HLA-homozygous clones from hiPSC-telHLAcNP/+ cells under the condition of BLM protein
suppression. (B) Schematic representation of the short arm of chromosome 6. After targeting the double selection cassette (telHLAcNP/+), an allele-specific DSB
was introduced between HLA class I and III genes. The HLA-heterozygous genotypes in parental cells are shown in the right panel. (C) Schematic
representation of the short arm of chromosome 6 after crossover. Patterns of heterozygous and LOH genotypes are shown in the left panel. HLA genotypes
after crossover in clone 1 are shown in the right panel. (D) SNP array analysis of hiPSC-telHLAcNP/+ML216(+)HLA I-III-CRISPR(+). (E) Flow cytometry
profile of the surface expression of the HLA-A haplotype A2 and A32 in hiPSCs.
https://doi.org/10.1371/journal.pone.0225740.g004
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most likely HLA heterozygous, are used for therapeutics as donor cells, the recipient must
have the same combination of HLA haplotypes. However, HLA matching between a donor
and recipient is very rare. Therefore, a bank of HLA-homozygous hiPSCs has been generated
[16]. For the HLA-homozygous bank, HLA-A, HLA-B, and HLA-DR were selected for match-
ing, but not HLA-C, HLA-DQ, or the minor histocompatibility antigens [16]. In contrast, our
strategy is able to induce HLA homozygosity across the entire region of the HLA locus. There-
fore, using this strategy, one could easily choose a much more compatible combination
between the donor of HLA-homozygous hiPSC-derived differentiated cells and the recipient
[17]. Although careful examination of HLA-homozygous hiPSCs is needed for cancer predis-
position and effectiveness of differentiation, they may facilitate hiPSC-based transplantation
related to the immunological differences between donors and hosts.
Other approaches to reduce the immunogenicity of hiPSCs and their derivatives have
included the generation of haplotype-specific HLA antigens or the complete deletion of HLA
antigens [11] [18] with the latter being accomplished by deletion of the HLA gene itself or
B2M gene targeting [19]. However, it has been shown that cells lacking HLA-C antigens are
susceptible to attack by natural killer cells [19] [20], posing a possible shortcoming. More
recently, Xu et al. reported that HLA-C-retaining hiPSCs with HLA-A and -B pseudo-homo-
zygosity and HLA-A and -B knockout generated by CRISPR/Cas9 showed enhanced immune
compatibility [21]. hiPSCs produced using this new method retained either one copy or no
copies of HLA-A and -B. However, our strategy allows retention of two homozygous copies of
all the HLA antigens, which is arguably a safer approach than deleting entire HLA antigens.
In conclusion, the method described in this study offers a novel genetic tool for human
biology.
Supporting information
S1 Fig. Removal of the selection cassette. (A) Schematic representation of the BLM locus
before and after removal of the selection cassette. Primers hBLM-endF and hBLM-endR were
used to detect the removal. (B) Analyses of colonies after Flpo transfection by PCR with prim-
ers hBLM-endF and hBLM-endR. The selection cassette was deleted in clones #1 and #2, but
not in clones #3–#6. M indicates the marker.
(PDF)
S2 Fig. Comparison of BLM transcripts between parental hiPSCs and hiPSC-BLMtet/tet by
RNA seq analyses. FPKM derived from hiPSC-BLMtet/tet was divided by that from hiPSCs.
(PDF)
S3 Fig. Measurement of BLM transcripts after 8 days of dox treatment. The method to
detect BLM transcripts was the same as that in Fig 1D.
(PDF)
S4 Fig. Efficiency of iCre-mediated cassette inversion. hiPSC-BLMtet/tetAAVScNP/+cells
(5×105) were transfected with EF1α-iCre or pBluescript (pBS), followed by selection with
either 100 μg/mL G418, 0.75 μg/mL puromycin, or both. The efficiency of Cre-mediated cas-
sette inversion was estimated at approximately 10 days after selection. Surviving colonies after
the selections were fixed and stained with Giemsa stain. They are shown with blue dots.
(PDF)
S5 Fig. Detection of positive clones bearing the crossover by genotyping of the AAVS1
locus in chromosome 19. (A) Candidate clones were analyzed by competitive PCR using
primers AAVS1-C-F, AAVS1-C-R, and Puro-L2 (S1 Table). hiPSC colonies after selection
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were picked up and applied to PCR analysis or culture in 96-well plates. (B) Wildtype, neomy-
cin resistance, and puromycin resistance alleles are represented by bands of 275, 407, and 1435
bp, respectively. The band derived from the wildtype allele is indicated by an asterisk. The pos-
itive pattern losing the band derived from the wildtype allele is shown in lane 3. M indicates
100 bp markers.
(PDF)
S6 Fig. Distribution of crossover points in chromosome 19. (A) Analyses of crossover points
in chromosome 19 (9Mb, 14Mb, and 19Mb). (B) LOH panel of crossover points at 14 Mb. (C)
LOH panel of crossover points at 19 Mb-I and 19 Mb-II.
(PDF)
S7 Fig. SNP array analyses of the whole genome. SNP array patterns were the same in hiPSCs
and two clones [hiPSC-BLMtet/tetAAVScNP/+DOX(+)9M-CRISPR(+) and hiPSC-BLMtet/
tetAAVScNP/+ML216(+)9M-CRISPR(+)] after crossovers except in predicted sites (red box).
hiPSCs had abnormal chromosomes 3 and 4 as indicated by a black box. These abnormalities
might have occurred during hiPSC generation, because parental fibroblasts did not contain
these abnormalities.
(PDF)
S8 Fig. Quantification of pluripotency marker gene expression. FPKM (fragments per kilo-
base of exon per million mapped reads) was calculated from total RNA of parental fibroblasts
(1), hiPSC-telHLAcNP/+ (2), and hiPSC-telHLAcNP/+ML216(+)HLA I-III-CRISPR(+) (3).
(n = 3, error bars show SEM).
(PDF)
S9 Fig. Flow cytometry profile of the surface expression of HLA-A haplotype A2 and A32
in hiPSCs-telHLAcNP/+.
(PDF)
S1 Table. Primers used for vector construction and PCR genotyping.
(PDF)
S2 Table. Sequences of TALENs.
(PDF)
S3 Table. CRISPR information.
(PDF)
S4 Table. Primers used for SNP typing.
(PDF)
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